Centre de Ressources et de Compétences Sclérose en plaques. AP-HP, Department of Neurology, Hôpital Pitié-Salpêtrière, Paris, France.
Department of Infectious Diseases, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
Mult Scler. 2021 Oct;27(11):1794-1798. doi: 10.1177/1352458521991433. Epub 2021 Feb 25.
Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.
已有报道显示，在使用芬戈莫德治疗多发性硬化症（MS）的患者中，出现了少数人类乳头瘤病毒（HPV）疾病病例。我们描述了一组 16 例 MS 患者（11 名女性，5 名男性）在使用芬戈莫德后出现 HPV 病变，且这些患者均无 HPV 既往史。6 名患者因出现 HPV 病变而停用芬戈莫德。6 名患者接受了 HPV 疫苗接种，且耐受性良好。我们的报告强调，在开始使用芬戈莫德之前，进行系统的 HPV 筛查和讨论 HPV 疫苗接种非常重要。如果在使用芬戈莫德治疗期间出现 HPV 病变，需要对 HPV 疾病进行全面检查，并讨论接种 HPV 疫苗以预防继发病变。需要对使用不同疾病修正治疗的 MS 患者进行 HPV 病变的患病率研究。
